Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $15
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Bioventus (BVS), Corvus Pharmaceuticals (CRVS) and Lifecore Biomedical (LFCR)
Press Release: Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners
Express News | Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners
could pop any minute or could take months..who knows
️ 
